US20180327801A1 - METHOD FOR PREPARING RECOMBINANT PROTEINS THROUGH REDUCTION OF rnpA GENE EXPRESSION - Google Patents

METHOD FOR PREPARING RECOMBINANT PROTEINS THROUGH REDUCTION OF rnpA GENE EXPRESSION Download PDF

Info

Publication number
US20180327801A1
US20180327801A1 US16/027,478 US201816027478A US2018327801A1 US 20180327801 A1 US20180327801 A1 US 20180327801A1 US 201816027478 A US201816027478 A US 201816027478A US 2018327801 A1 US2018327801 A1 US 2018327801A1
Authority
US
United States
Prior art keywords
protein
expression
gene
srna
rnpa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/027,478
Inventor
Sang Yup Lee
Hannah Chung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicosbiotech Inc
Original Assignee
Korea Advanced Institute of Science and Technology KAIST
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/KR2015/013419 external-priority patent/WO2016093606A1/en
Application filed by Korea Advanced Institute of Science and Technology KAIST filed Critical Korea Advanced Institute of Science and Technology KAIST
Priority to US16/027,478 priority Critical patent/US20180327801A1/en
Publication of US20180327801A1 publication Critical patent/US20180327801A1/en
Assigned to MEDICOSBIOTECH, INC. reassignment MEDICOSBIOTECH, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/26Endoribonucleases producing 5'-phosphomonoesters (3.1.26)
    • C12Y301/26005Ribonuclease P (3.1.26.5)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00Production
    • C12N2330/50Biochemical production, i.e. in a transformed host cell

Definitions

  • the present invention relates to a method for improving the production of a recombinant protein in a recombinant microorganism, and more particularly to a method for improving the production of a recombinant protein by use of a recombinant microorganism into which a gene encoding a target protein and an sRNA against a gene encoding ribonuclease P are introduced.
  • the useful protein to be produced is larger in size than a naturally occurring protein or is difficult to express, many problems may arise. If the size of a protein is large, translation of the protein may be difficult due to lack of messanger RNA (mRNA), and thus expression of the desired full-length protein may be difficult.
  • mRNA messanger RNA
  • a recombinant protein that is not naturally present in E is not naturally present in E.
  • coli may be difficult to express, due to proteolysis and RNase-induced degradation of mRNA (GoBringer et al., J Bacteriol., 188: 6816, 2006; Olson et al., PLoS Pathog., 7(2): e1001287, 2011; Jung et al., Biochem Biophys Res Commun., 186(3):1463, 1992; Altman et al., Phil Trans R Soc., 366, 2011; Turrini et al., PLos One., 7(3): e32456, 2012).
  • the present inventors have made extensive efforts to develop a protein expression system for increasing the production of a difficult-to-express foreign protein, and as a result, have found that, when expression of the rnpA gene (which is a component of ribonuclease P) in a process of expressing the foreign protein by introducing a gene encoding the foreign protein is reduced, expression of the difficult-to-express foreign protein increases, thereby completing the present invention.
  • the rnpA gene which is a component of ribonuclease P
  • Another object of the present invention is to provide a method for producing a target protein by culturing the above-described recombinant microorganism.
  • the present invention provides a recombinant vector for expressing a target protein, which comprises a gene encoding the target protein and an sRNA against a gene encoding ribonuclease P, and a recombinant microorganism into which the recombinant vector is introduced.
  • the present invention also provides a recombinant microorganism into which a gene encoding a target protein and an sRNA against a gene encoding ribonuclease P are introduced.
  • the present invention also provides a method for producing a target protein, the method comprising the steps of: (a) producing the target protein by culturing the above-described recombinant microorganism and inducing expression of the target protein in the recombinant microorganism; and (b) recovering the produced target protein.
  • the present invention also provides a method for producing a target protein, comprising the steps of: expressing and producing the target protein by culturing a recombinant microorganism into which a gene encoding the target protein is introduced; and recovering the produced target protein, wherein expression of ribonuclease P is reduced to increase expression of the target protein.
  • FIG. 1 is a gene map of the plasmid pTetly2glyAN-rnpA(sRNA).
  • FIG. 2 shows the results of analyzing expression levels of a silk protein consisting of 16 repeats and a silk protein consisting of 32 repeats by SDS-PAGE.
  • Lane 1 a marker showing protein standard molecular weight
  • lanes 2 and 3 the results of inducing protein expression in a stain transformed with the plasmid pSH16 at an OD600 of 0.4
  • lanes 4 and 5 the results of inducing protein expression in a strain transformed with the plasmid pSH16 and pACYC184-rnpA(sRNA) at an OD600 of 0.4
  • lanes 6 and 7 the results of inducing protein expression in a strain transformed with the plasmid pSH32 at an OD 600 of 0.4
  • lanes 8 and 9 the results of inducing protein expression in a strain transformed with the plasmid pSH32 and pACYC184-rnpA(sRNA) at an OD600 of 0.4.
  • FIG. 3 shows the results of analyzing expression levels of a silk protein consisting of 64 repeats by SDS-PAGE.
  • lane 1 a marker showing protein standard molecular weight
  • lane 2 the result of inducing protein expression in a strain transformed with pSH64 at an OD600 of 0.4
  • lane 3 the result of inducing protein expression in a strain transformed with the plasmid pSH64 and pACYC184-rnpA(sRNA) at an OD600 of 0.4.
  • FIG. 4A shows the results of analyzing expression levels of a silk protein consisting of 96 repeats by SDS-PAGE.
  • lane 1 a marker showing protein standard molecular weight
  • lane 2 the result of inducing protein expression in a strain transformed with pSH96 at an OD 600 of 0.4
  • lane 3 the result of inducing protein expression in a strain transformed with the plasmid pSH96 and pACYC184-rnpA(sRNA) at an OD 600 of 0.4.
  • FIG. 4B shows the results obtained by inducing protein expression in strains transformed with the plasmid pSH96 and the plasmid pSH96 plus pTetgly2glyAN-rnpA(sRNA), respectively, at an OD 600 of 0.4, analyzing protein expression levels by SDS-PAGE, quantifying the protein expression levels using a densitometer, and then averaging the protein expression levels.
  • FIG. 5 shows the result of analyzing expression levels of a silk protein consisting of 128 repeats by SDS-PAGE.
  • lane 1 a marker showing protein standard molecular weight
  • lane 2 the result of inducing protein expression in a strain transformed with pSH128 at an OD600 of 0.4
  • lane 3 the result of inducing protein expression in a strain transformed with pSH128 and pACYC184-rnpA(sRNA) at an OD 600 of 0.4.
  • FIG. 6 is a graph showing the results of examining whether the level of intracellular mRNA is increased by reducing expression of the rnpA gene.
  • FIG. 7A is a graph showing the amount of a silk protein consisting of 96 repeats, produced by fed-batch culture, and FIG. 7B shows the results of electrophoresis of the protein.
  • FIG. 8 shows the results of electrophoresis performed using a system for reducing expression of the rnpA gene according to the present invention in order to confirm increased expressions of difficult-to-express proteins other than the silk protein.
  • electrophoresis image (a) shows the results of analyzing the expression level of malic enzyme (SfcA) by SDS-PAGE.
  • Electrophoresis image shows the results of analyzing the expression level of Cat2 by SDS-PAGE.
  • Electrophoresis image (c) shows the results of analyzing the expression level of SrtA by SDS-PAGE.
  • Electrophoresis image shows the results of analyzing the expression level of CYP73A5 by SDS-PAGE.
  • Electrophoresis image shows the results of analyzing the expression level of CYP98A3 by SDS-PAGE.
  • lanes 1 and 3 the results of inducing protein expression in a strain transformed with CYP98A3 at an OD 600 of 0.4
  • lanes 4 and 5 the results of inducing protein expression in a strain transformed with CYP98A3-rnpA(sRNA) at an OD 600 of 0.4
  • the present inventors have developed a method for improving expression of a difficult-to-express recombinant protein, which was not easily produced in the prior art, in a recombinant microorganism by reducing expression of ribonuclease P to increase the mRNA level of a useful protein in cells.
  • the term “difficult-to-express protein” refers to a protein having a molecular weight of 50 kDa or more.
  • the present invention is directed to a recombinant vector for expressing a target protein, which comprises a gene encoding the target protein and an sRNA against a gene encoding ribonuclease P, and to a recombinant microorganism transformed with the recombinant vector.
  • the target protein may be a protein selected from among difficult-to-express proteins silk proteins, antibodies, enzymes, cytochromes, and sortase A, but is not limited thereto.
  • the sRNA may be an sRNA against an rnpA gene, and may have a nucleotide sequence set forth in any one of SEQ ID NOs: 1 to 3, but is not limited thereto as long as it reduces the expression of an rnpA gene.
  • examples of microorganisms for production of proteins may include Escherichia, Pseudomonas, Saccharomyces, and the like, and may be preferably an Escherichia microorganism, most preferably E. coli.
  • E. coli can be easily industrialized since genetic information and culture conditions that are widely used industrially are very well known.
  • a recombinant E. coli strain was constructed by transformation with a gene encoding a silk protein resulting from modification of a dragline silk protein obtained from Nephila clavipes, a nucleotide sequence encoding glycine tRNA, and an sRNA for reducing expression of the RnpA that is a component of ribonuclease P.
  • the constructed recombinant E. coli strain was cultured. As a result, it could be seen that the protein of the silk protein increased 3-fold or more.
  • a malic enzyme-encoding gene sfcA
  • a sortase A-encoding gene srtA
  • a 4-hydroxybutyrate coenzyme A transferase-encoding gene Cat2
  • the cytochrome P450 gene CYP73A5; cinnamate 4-hydrosylase and CYP98A3
  • the present invention is directed to a recombinant microorganism into which a gene encoding a target protein and an sRNA against a gene encoding ribonuclease P are introduced.
  • the gene encoding the target protein and the sRNA against the gene encoding ribonuclease P may be present in the respective vectors or may be incorporated into the microbial chromosome.
  • the present invention is directed to a method for producing a difficult-to-express target protein, the method comprising the steps of: (a) producing the target protein by culturing the recombinant microorganism and inducing expression of the target protein in the recombinant microorganism; and (b) recovering the produced target protein.
  • a recombinant E. coli strain was constructed by transformation with a gene encoding a silk protein, a nucleotide sequence encoding glycine tRNA, and an sRNA for reducing expression of the rnpA gene that is a component of ribonuclease P.
  • the constructed recombinant E. coli strain was cultured. As a result, it could be seen that the protein of the silk protein increased 3-fold or more.
  • the target protein may be a large protein having a molecular weight of 50 kDa or more as a difficult-to-express protein.
  • the target protein may be a protein selected from a group consisting of silk proteins, antibodies, enzymes, cytochromes, and sortase A, but is not limited thereto.
  • the present invention is directed to a method for producing a target protein, comprising the steps of: expressing and producing the target protein by culturing a recombinant microorganism into which a gene encoding the target protein is introduced; and recovering the produced target protein, wherein expression of ribonuclease P in the recombinant microorganism is reduced to increase expression of the target protein.
  • the target protein may be a difficult-to-express protein or a protein having a molecular weight of 50 kDa or more, and a substance of inhibiting the expression of ribonuclease P may be added.
  • sRNA small RNA
  • sRNA refers to a short-length RNA, which is usually 200 or less nucleotides in length, which is not translated into protein and effectively inhibits the translation of a specific mRNA by complementary binding.
  • ribosome binding site refers to a site where ribosome binds to mRNA for the transcription of the mRNA.
  • the term “gene” is intended to have the broadest meaning, and the gene can encode a structural protein or a regulatory protein.
  • the regulatory protein includes a transcriptional factor, a heat shock protein, or a protein that is involved in DNA/RNA replication, transcription and/or translation.
  • the target gene whose expression is to be inhibited may be present as an extrachromosomal element.
  • the term “vector” means a DNA construct containing a DNA sequence operably linked to a suitable control sequence capable of effecting the expression of the DNA in a suitable host.
  • the vector may be a plasmid, a phage particle, or simply a potential genomic insert. Once incorporated into a suitable host, the vector may replicate and function independently of the host genome, or may in some instances, integrate into the genome itself.
  • plasmid and vector are sometimes used interchangeably, as the plasmid is the most commonly used form of vector.
  • the plasmid vector is preferably used.
  • a typical plasmid vector which can be used for this purpose contains: (a) a replication origin by which replication occurs efficiently such that several hundred plasmid vectors per host cell are created; (b) an antibiotic-resistant gene by which host cells transformed with the plasmid vector can be selected; and (c) restriction enzyme cutting sites into which foreign DNA fragments can be inserted. Even if suitable restriction enzyme cutting sites are not present in the vector, the use of a conventional synthetic oligonucleotide adaptor or linker enables the easy ligation between the vector and the foreign DNA fragments. After ligation, the vector should be transformed into suitable host cells.
  • the transformation can be easily achieved by the calcium chloride method or electroporation (Neumann, et al., EMBO J., 1:841, 1982).
  • a publicly known expression vector in the art may be used as a vector for expressing sRNA according to the present invention.
  • a nucleic acid sequence is operably linked when it is placed into arranged in a functional relationship with another nucleic acid sequence.
  • the nucleotide sequence may be a gene and a control sequence(s) linked to be capable of expressing the gene when a suitable molecule binds to a control sequence(s) (e.g., transcription-activating protein).
  • DNA for a pre-sequence or a secretory leader is operably linked to a DNA encoding a polypeptide when expressed as a pre-protein participating in secretion of the polypeptide; a promoter or an enhancer is operably linked to a coding sequence when affecting the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence when affecting the transcription of the sequence, or to a coding sequence when arranged to facilitate translation.
  • the term “operably linked” means that the DNA linked sequences are contiguous, and in the case of the secretory leader, are contiguous and present in a reading frame.
  • an enhancer is not necessarily contiguous. The linkage between these sequences is performed by ligation at a convenient restriction enzyme site. However, when this site does not exist, a synthetic oligonucleotide adaptor or a linker is used according to a conventional method.
  • the present invention is directed to a recombinant microorganism into which an expression vector comprising a nucleic acid encoding the sRNA is introduced.
  • transformation means that DNA can be replicated as a factor outside of chromosome or by means of completion of the entire chromosome by introducing DNA as a host.
  • vectors and expression control sequences do not equally function to express DNA sequences according to the present invention.
  • hosts do not equally function with respect to the same expression system.
  • one skilled in the art may appropriately select from a group consisting of various vectors, expression control sequences, and hosts without either departing from the scope of the present invention or bearing excessive experimental burden.
  • a vector must be selected considering a host, because the vector must be replicated in the host.
  • the copy number of the vector, the ability of regulating the copy number and the expression of other protein encoded by the corresponding vector should also be considered.
  • sRNA system To introduce an sRNA system into a pTetlgy2glyAN vector (Korean Patent No. 1147860), genetic manipulation was performed, and to obtain a ribosome binding site that is involved in translation of the rnpA gene, inverse-PCR was performed using primers of SEQ ID NOs: 4 and 5, thereby obtaining an rnpA sRNA (SEQ ID NO: 1).
  • SEQ ID NO: 4 5′-cctgggaaatgcgagcttaaccactttctgttgggccattgcattg- 3′
  • SEQ ID NO: 5 5′-GCAACCATTATCACCGCCA-3
  • the PCR reaction was performed using Pfu polymerase (SolGent, Korea) under the following conditions: pre-denaturation at 95° C. for 5 min, and then 28 cycles, each consisting of denaturation at 95° C. for 30 sec, annealing at 57° C. for 180 sec, and extension at 72° C. for 60 sec, followed by final extension at 72° C. for 5 min.
  • Pfu polymerase SolGent, Korea
  • the PCR product was electrophoresed on agarose gel to obtain a purified 5000-bp PCR product.
  • the purified PCR product was incubated with the restriction enzyme DpnI (New England Biolabs, USA) for 1 hour, and then ligated with a pTetlgy2glyAN by T4 DNA ligase(Roche, Germany), and the resulting vector was transformed into E. coli dH5 ⁇ (FhuA2 lac(del)U169 phoA glnV44 ⁇ 80′ lacZ(del)M15 gyrA96 recAl relAl endAl thi-1 hsdR17, Invitrogen).
  • the transformed strain was selected on an LB agar solid medium (tryptone 10 g/L, yeast extract 5 g/L, NaCl 5 g/L, and agar 15 g/L) containing 34 mg/L of chloramphenicol, thereby obtaining the recombinant plasmid pTetgly2glyAN-rnpA(sRNA) ( FIG. 1 ).
  • the constructed recombinant plasmid was confirmed by cleaving with restriction enzymes and DNA sequencing.
  • the plasmid pSH16a (Lee et al., Fischs and Applications of Chem. Eng., 8:3969, 2002) consisting of 16 repeats of the gene encoding the silk protein was digested with the restriction enzyme SpeI and NheI to obtain a 1.7-kb fragment. The fragment was ligated with the plasmid pSH16a digested with the restriction enzyme SpeI, thereby obtaining the recombinant plasmid pSH32. The direction of the ligated insert was determined by digestion with the restriction enzyme SpeI and NheI (New England Biolabs, USA).
  • the plasmid pSH16a was digested with the restriction enzyme SpeI and NheI to obtain a 1.7-kb fragment which was then ligated with the plasmid pSH32 digested with the restriction enzyme SpeI, thereby constructing the recombinant plasmid pSH48.
  • the recombinant plasmid pSH32 was digested with the restriction enzyme SpeI and NheI to obtain a 3.4-kb fragment which was then ligated with the plasmid pSH64 digested with the restriction enzyme SpeI, thereby constructing the recombinant plasmid pSH64.
  • the plasmid pSH48 was digested with the restriction enzyme SpeI and NheI to obtain a 5.1-kb fragment which was then ligated with the plasmid pSH32 digested with the restriction enzyme SpeI, thereby constructing the recombinant plasmid pSH80.
  • the plasmid pSH16 was digested with the restriction enzyme SpeI and NheI to obtain a 1.74-kb fragment which was then ligated with the plasmid pSH80 digested with the restriction enzyme SpeI, thereby constructing the recombinant plasmid pSH96.
  • the plasmid pSH32 was digested with the restriction enzyme SpeI and NheI to obtain a 3.4-kb fragment which was then ligated with the plasmid pSH80 digested with the restriction enzyme SpeI, thereby constructing the recombinant plasmid pSH112.
  • the plasmid pSH64 was digested with the restriction enzyme SpeI and NheI to obtain a 7.8-kb fragment which was then ligated with the plasmid pSH64 digested with the restriction enzyme SpeI, thereby constructing the recombinant plasmid pSH128.
  • the direction of each ligated insert was determined by digestion with the restriction enzyme SpeI and NheI.
  • E. coli BL21 (DE3) (F-ompT hsdSB(rB- mB-) gal dcm (DE3) a prophage carrying the T7 RNA polymerase gene) (New England Biolabs, USA) was transformed with the plasmid pTetgly2glyAN-rnpA(sRNA) obtained in Example 1 and each of the plasmid pSH16, pSH32, pSH48, pSH64, pSH80, pSH96 and pSH112 containing 16, 32, 48, 64, 80, 96 and 112 repeats of the silk protein-encoding gene, respectively.
  • E. coli BL21 (DE3), transformed with the plasmid pACYC184 and each of pSH16, pSH32, pSH64, pSH96 and pSH128, was used.
  • Each of the transformed strains was seeded into 10 ml of an LB liquid medium (tryptone 10 g/L, yeast extract 5 g/L, and NaCl 5 g/L)(containing 34 mg/L of chloramphenicol, 25 mg/L of kanamycin and 1% arabinose) and shake-cultured at 25° C. and 220 rpm.
  • each of the strains was shake-cultured under the above-described medium conditions at 37° C. and 220 rpm.
  • Example 4 Examination of the Increase in mRNA Level Caused by the Reduction in Expression of rnpA Gene by sRNA System
  • E. coli BL21 (DE3) (F-ompT hsdSB(rB- mB-) gal dcm (DE3) a prophage carrying the T7 RNA polymerase gene) (New England Biolabs, USA) was transformed with the plasmid pTetgly2glyAN-rnpA(sRNA) obtained in Example 1 and pSH32.
  • E. coli BL21 (DE3), transformed with the plasmid pACYC184 and pSH32, was used.
  • Each of the transformed strains was seeded into 10 ml of an LB liquid medium (tryptone 10 g/L, yeast extract 5 g/L, and NaCl 5 g/L) (containing 34 mg/L of chloramphenicol, 25 mg/L of kanamycin and 1% arabinose) and shake-cultured at 25° C. and 220 rpm.
  • each of the strains was shake-cultured under the above-described medium conditions at 37° C. and 220 rpm.
  • RNA extraction 1 ml of Trizol was added to the cell pellet, after which the cell pellet solution was stirred for 1 minute and allowed to stand at room temperature for 5 minutes.
  • chloroform in an amount equal to 20% of the total volume was added to the cell pellet solution which was then stirred for 15 seconds and centrifuged at 13,000 rpm for 15 minutes.
  • the produced supernatant was transferred into a fresh tube, and the same amount of isopropanol was added thereto and carefully stirred. Then, the mixture was centrifuged at 13,000 rpm for 30 minutes, and the supernatant was discarded.
  • 1 ml of 70% ethanol was added to the remaining material which was then centrifuged at 13,000 rpm for 5 minutes, and the above procedure was repeated again.
  • RNA was adjusted to 500 ng, and 2 ⁇ l of dN9 primer was added thereto. Then, the reaction mixture was adjusted to a total volume of 20 ⁇ l using RNase-free distilled water. The PCR reaction was performed under the following conditions: initial annealing at 30° C. for 150 seconds, cDNA synthesis at 60° C. for 1 hour, and then heat inactivation at 95° C. for 300 seconds.
  • a reaction mixture having a total volume of 20 ⁇ l contained 8 ⁇ l of RNase-free distilled water, 10 ⁇ l of SYBR Green Mastermix (Enzynomics, Korea), 1 ⁇ l of a 1/10 dilution of the cDNA, and 0.5 ⁇ l of each primer.
  • the RT-PCR reaction was performed under the following conditions: initial activation at 95° C. for 10 minutes, and then 45 cycles, each consisting of denaturation at 95° C. for 30 sec, annealing at 60° C. for 30 sec, and extension at 72° C. for 30 sec. To determine the melting curve, the temperature was increased from 55° C. to 95° C. by 0.5° C., and the reaction mixture was maintained at each temperature for 5 seconds.
  • a 6.6-L fermentor Bioflo 3000; New Brunswick Scientific Co.
  • 1.6 L of R/2 medium 10 g/L of glucose, 0.7 g/L of MgSO 4 .7H 2 O, and an antibiotic (50 ⁇ g/mL kanamycin and/or 35 ⁇ g/mL chloramphenicol) were added to the strain in the fermentor.
  • an antibiotic 50 ⁇ g/mL kanamycin and/or 35 ⁇ g/mL chloramphenicol
  • air saturation was adjusted while the agitation speed was increased to 1000 rpm.
  • a feeding solution was composed of 700 g/L of glucose and 20 g/L MgSO 4 .7H 2 O, and the pH of the culture was adjusted using 28% (v/v) ammonia solution.
  • the OD600 reached about 70
  • 1 mM IPTG was added to the culture to induce protein expression.
  • the culture was sampled at 2-hour intervals.
  • Cell proliferation and the concentration of the protein obtained are shown in FIG. 7 .
  • the protein could be obtained at a concentration of 0.9 g/L, which was 30% higher than the previously known concentration (0.7 g/L).
  • the Sortase A gene was synthesized by Bioneer (Korea), and the sfcA, cat2, CYP73A5 and CYP98A3 genes were obtained by PCR using the following primers.
  • sfcA_F (SEQ ID NO: 11) 5′-CCATGGATATTCAAAAAAGAGTGAGT-3′ sfcA_R: (SEQ ID NO: 12) 5′-TCTAGATTAGATGGAGGTACGGCGGTA-3′
  • Cat2_F (SEQ ID NO: 13) 5′-GAATTCATGGAGTGGGAAGAGATATATA-3′
  • Cat2_R (SEQ ID NO: 14) 5′-GGTACCCTAAAATCTCTTTTTAAATTCATT-3′
  • CYP73A5_F (SEQ ID NO: 15) 5′-GCGAAGCTTACAGTTCCTTGGTTTCATAA-3′
  • CYP73A5_R (SEQ ID NO: 16) 5′-GTACATATGATGGACCTCCTCTTGCTGG-3′
  • CYP98A3_F (SEQ ID NO: 17) 5′-GGATCCATGTCGTGGTTTCTAATAGC-3′
  • CYP98A3_R (
  • RnpA sRNA (SEQ ID NO: 1) and each of the sfcA, srtA and cat2 genes were inserted into pET30a (+)(Addgene, USA) and pTac15k (Addgene, USA) respectively to obtain recombinant vectors.
  • Each of the vectors was transformed into an E. coli BL21 (DE3) strain.
  • E. coli BL21 (DE3) strain As a control, a strain transformed with a vector obtained by inserting each of the sfcA, srtA and cat2 genes into pET30a and pTac15k was used.
  • Each of the transformed strains was seeded into 10 ml of an LB liquid medium (tryptone 10 g/L, yeast extract 5 g/L, and NaCl 5 g/L) (containing 34 mg/L of chloramphenicol, 25 mg/L of kanamycin and 1% arabinose) and shake-cultured at 25° C. and 220 rpm.
  • LB liquid medium tryptone 10 g/L, yeast extract 5 g/L, and NaCl 5 g/L
  • each of the strains was shake-cultured under the above-described medium conditions at 37° C. and 220 rpm.
  • 1 mM IPTG was added to the medium to induce expression of each protein.
  • the culture was sampled and centrifuged at 4° C.
  • cell pellets were dissolved in TE buffer and 5 ⁇ Laemmli sample buffer. The same amount (0.024 mg) of the sample was separated on 10% SDS-PAGE gel and stained with Coomassie brilliant blue R250 (Bio-Rad, USA) solution.
  • a target protein particularly a difficult-to-express protein having a high molecular weight
  • expression of a target protein can be dramatically increased by reducing expression of the rnpA gene so that the present invention is useful for increasing the productivity of proteins.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Insects & Arthropods (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

A method is described for improving the production of a difficult-to-express recombinant protein in a recombinant microorganism, and more particularly a method for improving the production of a difficult-to-express recombinant protein by use of a recombinant microorganism into which a gene encoding a target protein and an sRNA against a gene encoding ribonuclease P are introduced. By the disclosed method, expressions of a large recombinant protein, a difficult-to-express protein and a useful protein can be dramatically increased by reducing expression of the rnpA gene.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a divisional under 35 U.S.C. § 120 of U.S. patent application Ser. No. 15/533,273 filed Jun. 5, 2017, which in turn is a U.S. national phase under the provisions of 35 U.S.C. § 371 of International Patent Application No. PCT/KR2015/013419 filed Dec. 9, 2015, which in turn claims priority of Korean Patent Application No. 10-2014-0175780 filed Dec. 9, 2014 and Korean Patent Application No. 10-2015-0174828 filed Dec. 9, 2015. The disclosures of U.S. patent application Ser. No. 15/533,273, International Patent Application No. PCT/KR2015/013419, Korean Patent Application No. 10-2014-0175780, and Korean Patent Application No. 10-2015-0174828 are hereby incorporated herein by reference in their respective entireties, for all purposes.
  • TECHNICAL FIELD
  • The present invention relates to a method for improving the production of a recombinant protein in a recombinant microorganism, and more particularly to a method for improving the production of a recombinant protein by use of a recombinant microorganism into which a gene encoding a target protein and an sRNA against a gene encoding ribonuclease P are introduced.
  • BACKGROUND ART
  • The development of genetic manipulation technology has led to many studies focused on producing large amounts of useful proteins using bacterial and a variety of animals and plants. Host cells for producing large amounts of useful proteins are present, including bacteria such as E. coli, and yeasts such as P. pastoris. Of these host cells, E. coli has been most widely used, and studies thereon have been most frequently conducted (Choi et al., Chem. Eng. Sci., 66: 876, 2006; Lee, Trends Biotechnol., 14:98, 1996).
  • However, if the useful protein to be produced is larger in size than a naturally occurring protein or is difficult to express, many problems may arise. If the size of a protein is large, translation of the protein may be difficult due to lack of messanger RNA (mRNA), and thus expression of the desired full-length protein may be difficult. In addition, a recombinant protein that is not naturally present in E. coli may be difficult to express, due to proteolysis and RNase-induced degradation of mRNA (GoBringer et al., J Bacteriol., 188: 6816, 2006; Olson et al., PLoS Pathog., 7(2): e1001287, 2011; Jung et al., Biochem Biophys Res Commun., 186(3):1463, 1992; Altman et al., Phil Trans R Soc., 366, 2011; Turrini et al., PLos One., 7(3): e32456, 2012).
  • Accordingly, the present inventors have made extensive efforts to develop a protein expression system for increasing the production of a difficult-to-express foreign protein, and as a result, have found that, when expression of the rnpA gene (which is a component of ribonuclease P) in a process of expressing the foreign protein by introducing a gene encoding the foreign protein is reduced, expression of the difficult-to-express foreign protein increases, thereby completing the present invention.
  • DISCLOSURE OF INVENTION Technical Problem
  • It is a main object of the present invention to provide a recombinant microorganism into which a gene encoding a target protein and an sRNA against a gene encoding Ribonuclease P are introduced to increase the production of a difficult-to-express foreign protein.
  • Another object of the present invention is to provide a method for producing a target protein by culturing the above-described recombinant microorganism.
  • Technical Solution
  • To achieve the above objects, the present invention provides a recombinant vector for expressing a target protein, which comprises a gene encoding the target protein and an sRNA against a gene encoding ribonuclease P, and a recombinant microorganism into which the recombinant vector is introduced.
  • The present invention also provides a recombinant microorganism into which a gene encoding a target protein and an sRNA against a gene encoding ribonuclease P are introduced.
  • The present invention also provides a method for producing a target protein, the method comprising the steps of: (a) producing the target protein by culturing the above-described recombinant microorganism and inducing expression of the target protein in the recombinant microorganism; and (b) recovering the produced target protein.
  • The present invention also provides a method for producing a target protein, comprising the steps of: expressing and producing the target protein by culturing a recombinant microorganism into which a gene encoding the target protein is introduced; and recovering the produced target protein, wherein expression of ribonuclease P is reduced to increase expression of the target protein.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
  • FIG. 1 is a gene map of the plasmid pTetly2glyAN-rnpA(sRNA).
  • FIG. 2 shows the results of analyzing expression levels of a silk protein consisting of 16 repeats and a silk protein consisting of 32 repeats by SDS-PAGE. (lane 1: a marker showing protein standard molecular weight; lanes 2 and 3: the results of inducing protein expression in a stain transformed with the plasmid pSH16 at an OD600 of 0.4; lanes 4 and 5: the results of inducing protein expression in a strain transformed with the plasmid pSH16 and pACYC184-rnpA(sRNA) at an OD600 of 0.4; lanes 6 and 7: the results of inducing protein expression in a strain transformed with the plasmid pSH32 at an OD600 of 0.4; and lanes 8 and 9: the results of inducing protein expression in a strain transformed with the plasmid pSH32 and pACYC184-rnpA(sRNA) at an OD600 of 0.4.)
  • FIG. 3 shows the results of analyzing expression levels of a silk protein consisting of 64 repeats by SDS-PAGE. (lane 1: a marker showing protein standard molecular weight; lane 2: the result of inducing protein expression in a strain transformed with pSH64 at an OD600 of 0.4; and lane 3: the result of inducing protein expression in a strain transformed with the plasmid pSH64 and pACYC184-rnpA(sRNA) at an OD600 of 0.4.)
  • FIG. 4A shows the results of analyzing expression levels of a silk protein consisting of 96 repeats by SDS-PAGE. (lane 1: a marker showing protein standard molecular weight; lane 2: the result of inducing protein expression in a strain transformed with pSH96 at an OD600 of 0.4; and lane 3: the result of inducing protein expression in a strain transformed with the plasmid pSH96 and pACYC184-rnpA(sRNA) at an OD600 of 0.4.)
  • FIG. 4B shows the results obtained by inducing protein expression in strains transformed with the plasmid pSH96 and the plasmid pSH96 plus pTetgly2glyAN-rnpA(sRNA), respectively, at an OD600 of 0.4, analyzing protein expression levels by SDS-PAGE, quantifying the protein expression levels using a densitometer, and then averaging the protein expression levels.
  • FIG. 5 shows the result of analyzing expression levels of a silk protein consisting of 128 repeats by SDS-PAGE. (lane 1: a marker showing protein standard molecular weight; lane 2: the result of inducing protein expression in a strain transformed with pSH128 at an OD600 of 0.4; and lane 3: the result of inducing protein expression in a strain transformed with pSH128 and pACYC184-rnpA(sRNA) at an OD600 of 0.4.)
  • FIG. 6 is a graph showing the results of examining whether the level of intracellular mRNA is increased by reducing expression of the rnpA gene.
  • FIG. 7A is a graph showing the amount of a silk protein consisting of 96 repeats, produced by fed-batch culture, and FIG. 7B shows the results of electrophoresis of the protein.
  • FIG. 8 shows the results of electrophoresis performed using a system for reducing expression of the rnpA gene according to the present invention in order to confirm increased expressions of difficult-to-express proteins other than the silk protein. Specifically, electrophoresis image (a) shows the results of analyzing the expression level of malic enzyme (SfcA) by SDS-PAGE. (lane 1: a marker showing protein standard molecular weight; lane 2: the result of inducing protein expression in non-transformed BL21(DE3); lanes 3 and 4: the results of inducing protein expression in a strain transformed with SfcA at an OD600 of 0.4; and lanes 5 and 6: the results of inducing protein expression in a strain transformed with SfcA and rnpA(sRNA) at an OD600 of 0.4). Electrophoresis image (b) shows the results of analyzing the expression level of Cat2 by SDS-PAGE. (lane 1: a marker showing protein standard molecular weight; lanes 2 and 3: the results of inducing protein expression in a strain transformed with Cat2 at an OD600 of 0.4; and lanes 4 and 5: the results of inducing protein expression in a strain transformed with Cat2-rnpA(sRNA) at an OD600 of 0.4). Electrophoresis image (c) shows the results of analyzing the expression level of SrtA by SDS-PAGE. (lane 1: a marker showing protein standard molecular weight; lanes 2 and 3: the results of inducing protein expression in a strain transformed with SrtA at an OD600 of 0.4; and lanes 4 and 5: the results of inducing protein expression in a strain transformed with srtA-rnpA(sRNA) at an OD600 of 0.4). Electrophoresis image (d) shows the results of analyzing the expression level of CYP73A5 by SDS-PAGE. (lane 1: a marker showing protein standard molecular weight; lanes 2 and 3: the results of inducing protein expression in a strain transformed with CYP73A5at an OD600 of 0.4; and lanes 4 and 5: the results of inducing protein expression in a strain transformed with CYP73A5-rnpA(sRNA) at an OD600 of 0.4). Electrophoresis image (e) shows the results of analyzing the expression level of CYP98A3 by SDS-PAGE. (lane 1: a marker showing protein standard molecular weight; lanes 2 and 3: the results of inducing protein expression in a strain transformed with CYP98A3 at an OD600 of 0.4; and lanes 4 and 5: the results of inducing protein expression in a strain transformed with CYP98A3-rnpA(sRNA) at an OD600 of 0.4).
  • BEST MODE FOR CARRYING OUT THE INVENTION
  • The present inventors have developed a method for improving expression of a difficult-to-express recombinant protein, which was not easily produced in the prior art, in a recombinant microorganism by reducing expression of ribonuclease P to increase the mRNA level of a useful protein in cells.
  • In the present invention, expression of the rnpA gene that is a component of ribonuclease P was reduced using a sRNA system comprising sRNA, and as a result, it was shown that expression of a high-molecular-weight silk protein that is a difficult-to-express protein was increased dramatically.
  • As used herein, the term “difficult-to-express protein” refers to a protein having a molecular weight of 50 kDa or more.
  • Therefore, in one aspect, the present invention is directed to a recombinant vector for expressing a target protein, which comprises a gene encoding the target protein and an sRNA against a gene encoding ribonuclease P, and to a recombinant microorganism transformed with the recombinant vector.
  • In the present invention, the target protein may be a protein selected from among difficult-to-express proteins silk proteins, antibodies, enzymes, cytochromes, and sortase A, but is not limited thereto.
  • In the present invention, the sRNA may be an sRNA against an rnpA gene, and may have a nucleotide sequence set forth in any one of SEQ ID NOs: 1 to 3, but is not limited thereto as long as it reduces the expression of an rnpA gene.
  • In the present invention, examples of microorganisms for production of proteins that can be used may include Escherichia, Pseudomonas, Saccharomyces, and the like, and may be preferably an Escherichia microorganism, most preferably E. coli. In particular, it is advantageous that E. coli can be easily industrialized since genetic information and culture conditions that are widely used industrially are very well known.
  • In an example of the present invention, a recombinant E. coli strain was constructed by transformation with a gene encoding a silk protein resulting from modification of a dragline silk protein obtained from Nephila clavipes, a nucleotide sequence encoding glycine tRNA, and an sRNA for reducing expression of the RnpA that is a component of ribonuclease P. The constructed recombinant E. coli strain was cultured. As a result, it could be seen that the protein of the silk protein increased 3-fold or more. In addition, it was shown that expression of a silk protein consisting of 16, 32, 48, 64, 80, 96, 112 and 128 repeats of a specific amino acid sequence (SGRGGLGGTGAGMAAAAAMGGAGQGGYGGLGSQG) (SEQ ID NO: 19) was dramatically increased by reducing expression of the rnpA gene that is a component of ribonuclease P. Furthermore, it was shown that expressions of eGFP, SfcA and a full-length IgG antibody were also dramatically increased by reducing expression of the rnpA gene that is a component of ribonuclease P.
  • In view of the results indicating that the production of a long recombinant protein or a difficult-to-express protein is increased by reducing expression of the rnpA gene that is a component of ribonuclease P, it will be obvious to those skilled in the art that the degradation of messenger RNA (mRNA) has a great influence on protein expression and that overexpression of a target protein can be effectively achieved by reducing expression of a gene associated with messenger RNA (mRNA) degradation.
  • In another example of the present invention, the expressions of a malic enzyme-encoding gene (sfcA), a sortase A-encoding gene (srtA), a 4-hydroxybutyrate coenzyme A transferase-encoding gene (Cat2) and the cytochrome P450 gene (CYP73A5; cinnamate 4-hydrosylase and CYP98A3) were examined using the system for reducing expression of the rnpA gene according to the present invention. As a result, it was shown that a strain expressing an sRNA against the rnpA gene together with the gene encoding each of the proteins showed a higher protein expression level compared to a strain expressing no sRNA (FIG. 8; see electrophoresis images (a) through (e)).
  • In another aspect, the present invention is directed to a recombinant microorganism into which a gene encoding a target protein and an sRNA against a gene encoding ribonuclease P are introduced.
  • In the present invention, the gene encoding the target protein and the sRNA against the gene encoding ribonuclease P may be present in the respective vectors or may be incorporated into the microbial chromosome.
  • In still another aspect, the present invention is directed to a method for producing a difficult-to-express target protein, the method comprising the steps of: (a) producing the target protein by culturing the recombinant microorganism and inducing expression of the target protein in the recombinant microorganism; and (b) recovering the produced target protein.
  • In an example of the present invention, a recombinant E. coli strain was constructed by transformation with a gene encoding a silk protein, a nucleotide sequence encoding glycine tRNA, and an sRNA for reducing expression of the rnpA gene that is a component of ribonuclease P. The constructed recombinant E. coli strain was cultured. As a result, it could be seen that the protein of the silk protein increased 3-fold or more.
  • In another example of the present invention, it was shown that, when a gene encoding eGFP protein, a gene encoding sfcA protein and a gene encoding a full-length IgG antibody protein were co-expressed with an sRNA against the rnpA gene, expressions of the proteins increased.
  • In the present invention, preferably, the target protein may be a large protein having a molecular weight of 50 kDa or more as a difficult-to-express protein. For example, the target protein may be a protein selected from a group consisting of silk proteins, antibodies, enzymes, cytochromes, and sortase A, but is not limited thereto.
  • In still another aspect, the present invention is directed to a method for producing a target protein, comprising the steps of: expressing and producing the target protein by culturing a recombinant microorganism into which a gene encoding the target protein is introduced; and recovering the produced target protein, wherein expression of ribonuclease P in the recombinant microorganism is reduced to increase expression of the target protein.
  • In the present invention, the target protein may be a difficult-to-express protein or a protein having a molecular weight of 50 kDa or more, and a substance of inhibiting the expression of ribonuclease P may be added.
  • Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Generally, the nomenclature used herein and the experiment methods, which will be described below, are those well known and commonly employed in the art.
  • The definition of main terms used in the detailed description of the invention is as follows.
  • As used herein, the term “sRNA (small RNA)” refers to a short-length RNA, which is usually 200 or less nucleotides in length, which is not translated into protein and effectively inhibits the translation of a specific mRNA by complementary binding.
  • As used herein, the term “ribosome binding site” refers to a site where ribosome binds to mRNA for the transcription of the mRNA.
  • As used herein, the term “gene” is intended to have the broadest meaning, and the gene can encode a structural protein or a regulatory protein. Herein, the regulatory protein includes a transcriptional factor, a heat shock protein, or a protein that is involved in DNA/RNA replication, transcription and/or translation. Also, the target gene whose expression is to be inhibited may be present as an extrachromosomal element.
  • As used herein, the term “vector” means a DNA construct containing a DNA sequence operably linked to a suitable control sequence capable of effecting the expression of the DNA in a suitable host. The vector may be a plasmid, a phage particle, or simply a potential genomic insert. Once incorporated into a suitable host, the vector may replicate and function independently of the host genome, or may in some instances, integrate into the genome itself. In the present specification, “plasmid” and “vector” are sometimes used interchangeably, as the plasmid is the most commonly used form of vector. For the purpose of the present invention, the plasmid vector is preferably used. A typical plasmid vector which can be used for this purpose contains: (a) a replication origin by which replication occurs efficiently such that several hundred plasmid vectors per host cell are created; (b) an antibiotic-resistant gene by which host cells transformed with the plasmid vector can be selected; and (c) restriction enzyme cutting sites into which foreign DNA fragments can be inserted. Even if suitable restriction enzyme cutting sites are not present in the vector, the use of a conventional synthetic oligonucleotide adaptor or linker enables the easy ligation between the vector and the foreign DNA fragments. After ligation, the vector should be transformed into suitable host cells. The transformation can be easily achieved by the calcium chloride method or electroporation (Neumann, et al., EMBO J., 1:841, 1982). A publicly known expression vector in the art may be used as a vector for expressing sRNA according to the present invention.
  • A nucleic acid sequence is operably linked when it is placed into arranged in a functional relationship with another nucleic acid sequence. The nucleotide sequence may be a gene and a control sequence(s) linked to be capable of expressing the gene when a suitable molecule binds to a control sequence(s) (e.g., transcription-activating protein). For example, DNA for a pre-sequence or a secretory leader is operably linked to a DNA encoding a polypeptide when expressed as a pre-protein participating in secretion of the polypeptide; a promoter or an enhancer is operably linked to a coding sequence when affecting the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence when affecting the transcription of the sequence, or to a coding sequence when arranged to facilitate translation. Generally, the term “operably linked” means that the DNA linked sequences are contiguous, and in the case of the secretory leader, are contiguous and present in a reading frame. However, an enhancer is not necessarily contiguous. The linkage between these sequences is performed by ligation at a convenient restriction enzyme site. However, when this site does not exist, a synthetic oligonucleotide adaptor or a linker is used according to a conventional method.
  • In addition, the present invention is directed to a recombinant microorganism into which an expression vector comprising a nucleic acid encoding the sRNA is introduced. As used herein, the term “transformation” means that DNA can be replicated as a factor outside of chromosome or by means of completion of the entire chromosome by introducing DNA as a host.
  • Of course, it should be understood that all vectors and expression control sequences do not equally function to express DNA sequences according to the present invention. Similarly, all hosts do not equally function with respect to the same expression system. However, one skilled in the art may appropriately select from a group consisting of various vectors, expression control sequences, and hosts without either departing from the scope of the present invention or bearing excessive experimental burden. For example, a vector must be selected considering a host, because the vector must be replicated in the host. Specifically, the copy number of the vector, the ability of regulating the copy number and the expression of other protein encoded by the corresponding vector (e.g., the expression of an antibiotic marker) should also be considered.
  • EXAMPLES
  • Hereinafter, the present invention will be described in further detail with reference to examples. It will be obvious to a person having ordinary skill in the art that these examples are for illustrative purposes only and are not to be construed to limit the scope of the present invention.
  • Example 1: Construction of Recombinant Plasmid pTetgly2glyAN-rnpA(sRNA)
  • All procedures for gene manipulation followed standardized methods (Sambrook et al., Molecular cloning: a laboratory manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989).
  • To introduce an sRNA system into a pTetlgy2glyAN vector (Korean Patent No. 1147860), genetic manipulation was performed, and to obtain a ribosome binding site that is involved in translation of the rnpA gene, inverse-PCR was performed using primers of SEQ ID NOs: 4 and 5, thereby obtaining an rnpA sRNA (SEQ ID NO: 1).
  • SEQ ID NO: 4:
    5′-cctgggaaatgcgagcttaaccactttctgttgggccattgcattg-
    3′
    SEQ ID NO: 5:
    5′-GCAACCATTATCACCGCCA-3
  • The PCR reaction was performed using Pfu polymerase (SolGent, Korea) under the following conditions: pre-denaturation at 95° C. for 5 min, and then 28 cycles, each consisting of denaturation at 95° C. for 30 sec, annealing at 57° C. for 180 sec, and extension at 72° C. for 60 sec, followed by final extension at 72° C. for 5 min.
  • The PCR product was electrophoresed on agarose gel to obtain a purified 5000-bp PCR product. The purified PCR product was incubated with the restriction enzyme DpnI (New England Biolabs, USA) for 1 hour, and then ligated with a pTetlgy2glyAN by T4 DNA ligase(Roche, Germany), and the resulting vector was transformed into E. coli dH5α (FhuA2 lac(del)U169 phoA glnV44 Φ80′ lacZ(del)M15 gyrA96 recAl relAl endAl thi-1 hsdR17, Invitrogen).
  • The transformed strain was selected on an LB agar solid medium (tryptone 10 g/L, yeast extract 5 g/L, NaCl 5 g/L, and agar 15 g/L) containing 34 mg/L of chloramphenicol, thereby obtaining the recombinant plasmid pTetgly2glyAN-rnpA(sRNA) (FIG. 1). The constructed recombinant plasmid was confirmed by cleaving with restriction enzymes and DNA sequencing.
  • Example 2: Construction of Recombinant Plasmids Containing the Gene Encoding High-Molecular-Weight Silk Protein
  • In order to construct a recombinant plasmid containing 32 repeats of a gene that encodes a silk protein resulting from modification of a Nephila clavipes derived dragline silk protein that is a difficult-to-express protein having a large size, the plasmid pSH16a (Lee et al., Theories and Applications of Chem. Eng., 8:3969, 2002) consisting of 16 repeats of the gene encoding the silk protein was digested with the restriction enzyme SpeI and NheI to obtain a 1.7-kb fragment. The fragment was ligated with the plasmid pSH16a digested with the restriction enzyme SpeI, thereby obtaining the recombinant plasmid pSH32. The direction of the ligated insert was determined by digestion with the restriction enzyme SpeI and NheI (New England Biolabs, USA).
  • Similarly, the plasmid pSH16a was digested with the restriction enzyme SpeI and NheI to obtain a 1.7-kb fragment which was then ligated with the plasmid pSH32 digested with the restriction enzyme SpeI, thereby constructing the recombinant plasmid pSH48. The recombinant plasmid pSH32 was digested with the restriction enzyme SpeI and NheI to obtain a 3.4-kb fragment which was then ligated with the plasmid pSH64 digested with the restriction enzyme SpeI, thereby constructing the recombinant plasmid pSH64. The plasmid pSH48 was digested with the restriction enzyme SpeI and NheI to obtain a 5.1-kb fragment which was then ligated with the plasmid pSH32 digested with the restriction enzyme SpeI, thereby constructing the recombinant plasmid pSH80. The plasmid pSH16 was digested with the restriction enzyme SpeI and NheI to obtain a 1.74-kb fragment which was then ligated with the plasmid pSH80 digested with the restriction enzyme SpeI, thereby constructing the recombinant plasmid pSH96. The plasmid pSH32 was digested with the restriction enzyme SpeI and NheI to obtain a 3.4-kb fragment which was then ligated with the plasmid pSH80 digested with the restriction enzyme SpeI, thereby constructing the recombinant plasmid pSH112. The plasmid pSH64 was digested with the restriction enzyme SpeI and NheI to obtain a 7.8-kb fragment which was then ligated with the plasmid pSH64 digested with the restriction enzyme SpeI, thereby constructing the recombinant plasmid pSH128. The direction of each ligated insert was determined by digestion with the restriction enzyme SpeI and NheI.
  • Example 3: Examination of the Increase in Silk Protein Expression Caused by the Reduction in Expression of rnpA Gene by sRNA System
  • In order to examine the effect of co-overexpressing the glycine tRNA gene and reducing the expression of the ribonuclease P (rnpA) gene by use of the sRNA system in silk protein production, E. coli BL21 (DE3) (F-ompT hsdSB(rB- mB-) gal dcm (DE3) a prophage carrying the T7 RNA polymerase gene) (New England Biolabs, USA) was transformed with the plasmid pTetgly2glyAN-rnpA(sRNA) obtained in Example 1 and each of the plasmid pSH16, pSH32, pSH48, pSH64, pSH80, pSH96 and pSH112 containing 16, 32, 48, 64, 80, 96 and 112 repeats of the silk protein-encoding gene, respectively.
  • As a control, E. coli BL21 (DE3), transformed with the plasmid pACYC184 and each of pSH16, pSH32, pSH64, pSH96 and pSH128, was used. Each of the transformed strains was seeded into 10 ml of an LB liquid medium (tryptone 10 g/L, yeast extract 5 g/L, and NaCl 5 g/L)(containing 34 mg/L of chloramphenicol, 25 mg/L of kanamycin and 1% arabinose) and shake-cultured at 25° C. and 220 rpm. Next, each of the strains was shake-cultured under the above-described medium conditions at 37° C. and 220 rpm. When the culture reached an OD600 of 0.4, 1 mM IPTG was added to the medium to induce expression of the silk protein gene. At 4 hours after induction of the expression, the culture was sampled and centrifuged at 4° C. and 10,000 g for 10 minutes, and the obtained cell pellets were dissolved in TE buffer and 5× Laemmli sample buffer. The same amount (0.024 mg) of the sample was separated using 10% SDS-PAGE gel, after which it was stained with Coomassie brilliant blue R250 (Bio-Rad, USA) solution and quantified using the GS-710 Calibrated Imaging Densitometer (Bio-Rad, USA) (see FIGS. 2, 3, 4A, and 4B).
  • Furthermore, expression of the strain transformed with the plasmid pSH96 and pTetgly2glyAN-rnpA(sRNA) was induced at an OD600 0.4, after which protein expression was analyzed by SDS-PAGE, quantified using a densitometer and averaged. The results are shown in FIG. 4B. In addition, the results of expression performed using the plasmid pSH128 are shown in FIG. 5.
  • As a result, it could be seen that, due to the reduction in expression of ribonuclease P (RnpA), expression of the silk protein consisting of 16 repeats was increased by about 150% compared to the control, and expression of the silk protein consisting of 32 repeats was increased by about 300% compared to the control. Furthermore, expression of the silk protein consisting of 48 repeats was increased by about 300%, and expression of the silk protein consisting of 64 repeats was increased by about 300%. In addition, expression of the silk protein consisting of 80 repeats was increased by about 300%, expression of the silk protein consisting of 112 repeats was increased by about 200%, and expression of the silk protein consisting of 128 repeats was increased by about 150%.
  • Example 4: Examination of the Increase in mRNA Level Caused by the Reduction in Expression of rnpA Gene by sRNA System
  • In this Example, in order to prevent the degradation of messenger RNA in the production of recombinant, difficult-to-express and useful proteins, expression of the rnpA gene that is a component of ribonuclease P was reduced by introduction of the sRNA system. In addition, whether the level of intracellular mRNA would be increased by the reduction in expression of the rnpA gene was examined.
  • Specifically, E. coli BL21 (DE3) (F-ompT hsdSB(rB- mB-) gal dcm (DE3) a prophage carrying the T7 RNA polymerase gene) (New England Biolabs, USA) was transformed with the plasmid pTetgly2glyAN-rnpA(sRNA) obtained in Example 1 and pSH32.
  • As a control, E. coli BL21 (DE3), transformed with the plasmid pACYC184 and pSH32, was used. Each of the transformed strains was seeded into 10 ml of an LB liquid medium (tryptone 10 g/L, yeast extract 5 g/L, and NaCl 5 g/L) (containing 34 mg/L of chloramphenicol, 25 mg/L of kanamycin and 1% arabinose) and shake-cultured at 25° C. and 220 rpm. Next, each of the strains was shake-cultured under the above-described medium conditions at 37° C. and 220 rpm. When the culture reached an OD600 of 0.4, 1 mM IPTG was added to the medium to induce expression of the silk protein gene. At 4 hours after induction of the expression, the culture was sampled and centrifuged at 4° C. and 10,000 g for 10 minutes to obtain cell pellets, and RNA was extracted from the cell pellets.
  • For RNA extraction, 1 ml of Trizol was added to the cell pellet, after which the cell pellet solution was stirred for 1 minute and allowed to stand at room temperature for 5 minutes. Next, chloroform in an amount equal to 20% of the total volume was added to the cell pellet solution which was then stirred for 15 seconds and centrifuged at 13,000 rpm for 15 minutes. The produced supernatant was transferred into a fresh tube, and the same amount of isopropanol was added thereto and carefully stirred. Then, the mixture was centrifuged at 13,000 rpm for 30 minutes, and the supernatant was discarded. Next, 1 ml of 70% ethanol was added to the remaining material which was then centrifuged at 13,000 rpm for 5 minutes, and the above procedure was repeated again. Next, the resulting material was dried at room temperature and dissolved in 30 μl of RNase-free distilled water. In order to replace the extracted RNA with complementary DNA (cDNA), qPCR was performed using Rocketstrip (Bioneer, Korea). The extracted RNA was adjusted to 500 ng, and 2 μl of dN9 primer was added thereto. Then, the reaction mixture was adjusted to a total volume of 20 μl using RNase-free distilled water. The PCR reaction was performed under the following conditions: initial annealing at 30° C. for 150 seconds, cDNA synthesis at 60° C. for 1 hour, and then heat inactivation at 95° C. for 300 seconds.
  • To perform RT-PCR using the prepared cDNA, a reaction mixture having a total volume of 20 μl contained 8 μl of RNase-free distilled water, 10 μl of SYBR Green Mastermix (Enzynomics, Korea), 1 μl of a 1/10 dilution of the cDNA, and 0.5 μl of each primer. The RT-PCR reaction was performed under the following conditions: initial activation at 95° C. for 10 minutes, and then 45 cycles, each consisting of denaturation at 95° C. for 30 sec, annealing at 60° C. for 30 sec, and extension at 72° C. for 30 sec. To determine the melting curve, the temperature was increased from 55° C. to 95° C. by 0.5° C., and the reaction mixture was maintained at each temperature for 5 seconds.
  • As a result, as shown in FIG. 6, in the case of cells in which expression of ribonuclease P (RnpA) was reduced, the level of mRNA was 24-fold higher than that in the control. This suggests that the degradation of mRNA is prevented by reducing expression of ribonuclease P (RnpA).
  • Example 5: Examination of Increase in Spider Silk Protein Production by Fed-Batch Fermentation
  • The strain transformed with the plasmid pSH96 and pACYC184-rnpA(sRNA), constructed in Example 3, was cultured by fed-batch fermentation, and an increase in protein production in the strain was examined.
  • For fed-batch fermentation, a 6.6-L fermentor (Bioflo 3000; New Brunswick Scientific Co.) was used, and 1.6 L of R/2 medium, 10 g/L of glucose, 0.7 g/L of MgSO4.7H2O, and an antibiotic (50 μg/mL kanamycin and/or 35 μg/mL chloramphenicol) were added to the strain in the fermentor. To adjust the dissolved oxygen level to 40%, air saturation was adjusted while the agitation speed was increased to 1000 rpm. A feeding solution was composed of 700 g/L of glucose and 20 g/L MgSO4.7H2O, and the pH of the culture was adjusted using 28% (v/v) ammonia solution. When the OD600 reached about 70, 1 mM IPTG was added to the culture to induce protein expression. For 8 hours after induction of the expression, the culture was sampled at 2-hour intervals. Cell proliferation and the concentration of the protein obtained are shown in FIG. 7. As can be seen in FIG. 7, the protein could be obtained at a concentration of 0.9 g/L, which was 30% higher than the previously known concentration (0.7 g/L).
  • Example 6: Examination of the Increase in Expression of Other Proteins by Reduction in Expression of rnpA Gene
  • Using the system for reducing rnpA gene expression according to the present invention, expressions of the gene (sfcA, SEQ ID NO: 6) encoding malic enzyme, the gene (srtA, SEQ ID NO: 7) encoding sortase A, the gene (cat2, SEQ ID NO: 8) encoding 4-hydroxybutyrate coenzyme A transferase and the cytochrome P450 gene (CYP73A5; cinnamate 4-hydrosylase:SEQ ID NO: 9 and CYP98A3:SEQ ID NO: 10) were analyzed, in addition to expression of the gene encoding silk protein. The Sortase A gene was synthesized by Bioneer (Korea), and the sfcA, cat2, CYP73A5 and CYP98A3 genes were obtained by PCR using the following primers.
  • sfcA_F:
    (SEQ ID NO: 11)
    5′-CCATGGATATTCAAAAAAGAGTGAGT-3′
    sfcA_R:
    (SEQ ID NO: 12)
    5′-TCTAGATTAGATGGAGGTACGGCGGTA-3′
    Cat2_F:
    (SEQ ID NO: 13)
    5′-GAATTCATGGAGTGGGAAGAGATATATA-3′
    Cat2_R:
    (SEQ ID NO: 14)
    5′-GGTACCCTAAAATCTCTTTTTAAATTCATT-3′
    CYP73A5_F:
    (SEQ ID NO: 15)
    5′-GCGAAGCTTACAGTTCCTTGGTTTCATAA-3′
    CYP73A5_R:
    (SEQ ID NO: 16)
    5′-GTACATATGATGGACCTCCTCTTGCTGG-3′
    CYP98A3_F:
    (SEQ ID NO: 17)
    5′-GGATCCATGTCGTGGTTTCTAATAGC-3′
    CYP98A3_R:
    (SEQ ID NO: 18)
    5′-GAATTCTTACATATCGTAAGGCACGC-3′
  • RnpA sRNA (SEQ ID NO: 1) and each of the sfcA, srtA and cat2 genes were inserted into pET30a (+)(Addgene, USA) and pTac15k (Addgene, USA) respectively to obtain recombinant vectors. Each of the vectors was transformed into an E. coli BL21 (DE3) strain. As a control, a strain transformed with a vector obtained by inserting each of the sfcA, srtA and cat2 genes into pET30a and pTac15k was used.
  • Each of the transformed strains was seeded into 10 ml of an LB liquid medium (tryptone 10 g/L, yeast extract 5 g/L, and NaCl 5 g/L) (containing 34 mg/L of chloramphenicol, 25 mg/L of kanamycin and 1% arabinose) and shake-cultured at 25° C. and 220 rpm. Next, each of the strains was shake-cultured under the above-described medium conditions at 37° C. and 220 rpm. When the culture reached an OD600 of 0.4, 1 mM IPTG was added to the medium to induce expression of each protein. At 4 hours after induction of the expression, the culture was sampled and centrifuged at 4° C. and 10,000 g for 10 minutes to obtain cell pellets. The cell pellets were dissolved in TE buffer and 5× Laemmli sample buffer. The same amount (0.024 mg) of the sample was separated on 10% SDS-PAGE gel and stained with Coomassie brilliant blue R250 (Bio-Rad, USA) solution.
  • As a result, as can be seen in FIG. 8 (see electrophoresis images (a) through (e) therein), the expression levels of malic enzyme, sortase A, 4-hydroxybutyrate coenzyme A transferase (Cat2) and cytochrome P450 (cinnamate 4-hydrosylase and CYP98A3), expressed together with the RnpA sRNA, were significantly higher than the expression levels of the proteins expressed in the absence of the RnpA sRNA.
  • Although the present invention has been described in detail with reference to the specific features, it will be apparent to those skilled in the art that this description is only for a preferred embodiment and does not limit the scope of the present invention. Thus, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.
  • INDUSTRIAL APPLICABILITY
  • According to the present invention, expression of a target protein, particularly a difficult-to-express protein having a high molecular weight can be dramatically increased by reducing expression of the rnpA gene so that the present invention is useful for increasing the productivity of proteins.

Claims (6)

What is claimed is:
1. A method for producing a target protein, comprising the steps of:
producing the target protein by culturing a recombinant microorganism into which a gene encoding the target protein is introduced; and
recovering the produced target protein,
wherein a substance of reducing expression of ribonuclease P is added in the culture to increase expression of the target protein.
2. The method of claim 1, wherein the target protein is a difficult-to-express protein or a protein having a molecular weight of 50 kDa or more.
3. The method of claim 1, wherein the target protein is a silk protein, antibody, cytochrome, enzyme, or sortase A.
4. The method of claim 1, wherein said substance is an sRNA.
5. The method of claim 1, wherein said sRNA is an sRNA against an rnpA gene.
6. The method of claim 1, wherein said sRNA has a nucleotide sequence of any one of SEQ ID NOS: 1 to 3.
US16/027,478 2014-12-09 2018-07-05 METHOD FOR PREPARING RECOMBINANT PROTEINS THROUGH REDUCTION OF rnpA GENE EXPRESSION Abandoned US20180327801A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/027,478 US20180327801A1 (en) 2014-12-09 2018-07-05 METHOD FOR PREPARING RECOMBINANT PROTEINS THROUGH REDUCTION OF rnpA GENE EXPRESSION

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
KR20140175780 2014-12-09
KR10-2014-0175780 2014-12-09
KR1020150174828A KR101765255B1 (en) 2014-12-09 2015-12-09 Method for Preparing Recombinant Proteins Through Reduced Expression of rnpA
PCT/KR2015/013419 WO2016093606A1 (en) 2014-12-09 2015-12-09 Method for preparing recombinant proteins through reduction of rnpa gene expression
KR10-2015-0174828 2015-12-09
US201715533273A 2017-06-05 2017-06-05
US16/027,478 US20180327801A1 (en) 2014-12-09 2018-07-05 METHOD FOR PREPARING RECOMBINANT PROTEINS THROUGH REDUCTION OF rnpA GENE EXPRESSION

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/KR2015/013419 Division WO2016093606A1 (en) 2014-12-09 2015-12-09 Method for preparing recombinant proteins through reduction of rnpa gene expression
US15/533,273 Division US10351890B2 (en) 2014-12-09 2015-12-09 Method for preparing recombinant proteins through reduction of rnpA gene expression

Publications (1)

Publication Number Publication Date
US20180327801A1 true US20180327801A1 (en) 2018-11-15

Family

ID=56344018

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/533,273 Active US10351890B2 (en) 2014-12-09 2015-12-09 Method for preparing recombinant proteins through reduction of rnpA gene expression
US16/027,478 Abandoned US20180327801A1 (en) 2014-12-09 2018-07-05 METHOD FOR PREPARING RECOMBINANT PROTEINS THROUGH REDUCTION OF rnpA GENE EXPRESSION

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US15/533,273 Active US10351890B2 (en) 2014-12-09 2015-12-09 Method for preparing recombinant proteins through reduction of rnpA gene expression

Country Status (3)

Country Link
US (2) US10351890B2 (en)
KR (1) KR101765255B1 (en)
CN (1) CN107208106A (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107881156A (en) * 2017-11-21 2018-04-06 上海海洋大学 Express GCRV spike protein VP56 recombinant baculovirus and application
KR102363366B1 (en) * 2018-11-23 2022-02-16 (주)메디코스바이오텍 Composition for Treating Alopecia or Stimulating Hair Growth
KR102488022B1 (en) * 2020-12-07 2023-01-13 (주)메디코스바이오텍 Recombinant Microorganism Having Enhanced Ability to Produce Recombinant Silk Protein and Method for Producing High Molecular Weight Recombinant Silk Protein Using The Same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936432B2 (en) * 2000-03-01 2005-08-30 Message Pharmaceuticals Bacterial RNase P proteins and their use in identifying antibacterial compounds
KR101147860B1 (en) 2008-09-22 2012-05-25 한국과학기술원 Method for Preparing Protein Having High Specific Amino Acid Content Through Co-expression of tRNA of Specific Amino Acid
CN103635191A (en) 2011-01-26 2014-03-12 罗切斯特大学 Small molecule RNASE inhibitors and methods of use
DK2803727T3 (en) 2012-01-11 2019-01-14 Korea Advanced Inst Sci & Tech SYNTHESIS REGULATORY SRNA AND METHOD OF PRODUCING THEREOF

Also Published As

Publication number Publication date
US20170342454A1 (en) 2017-11-30
KR101765255B1 (en) 2017-08-04
KR20160070028A (en) 2016-06-17
CN107208106A (en) 2017-09-26
US10351890B2 (en) 2019-07-16

Similar Documents

Publication Publication Date Title
Yim et al. Isolation of fully synthetic promoters for high‐level gene expression in Corynebacterium glutamicum
Opdyke et al. RNase III participates in GadY-dependent cleavage of the gadX-gadW mRNA
Liu et al. Expression of recombinant protein using Corynebacterium glutamicum: progress, challenges and applications
US20230287439A1 (en) Pathway integration and expression in host cells
Aw et al. Liquid PTVA: a faster and cheaper alternative for generating multi-copy clones in Pichia pastoris
US20180327801A1 (en) METHOD FOR PREPARING RECOMBINANT PROTEINS THROUGH REDUCTION OF rnpA GENE EXPRESSION
Gao et al. Three novel Escherichia coli vectors for convenient and efficient molecular biological manipulations
KR101659732B1 (en) Protein Expression System Induced by Heavy Metals And Biosensor for Detecting Heavy Metals
Gurung et al. Heterologous complementation studies with the YscX and YscY protein families reveals a specificity for Yersinia pseudotuberculosis type III secretion
Shen et al. Identification of a novel promoter for driving antibiotic-resistant genes to reduce the metabolic burden during protein expression and effectively select multiple integrations in Pichia Pastoris
US20070249042A1 (en) Strains of E. Coli for Plasmid Dna Production
Yun et al. The CnuK9E H-NS complex antagonizes DNA binding of DicA and leads to temperature-dependent filamentous growth in E. coli
Liu et al. Mini-Tn7 vectors for studying post-transcriptional gene expression in Pseudomonas
Mergulhao et al. Evaluation of inducible promoters on the secretion of a ZZ‐proinsulin fusion protein in Escherichia coli
Manna et al. Altering the selection capabilities of common cloning vectors via restriction enzyme mediated gene disruption
Gurvich et al. Two groups of phenylalanine biosynthetic operon leader peptides genes: a high level of apparently incidental frameshifting in decoding Escherichia coli pheL
CN114672449A (en) Strain for efficiently expressing lactoferrin by using temperature-sensitive promoter as well as construction method and application of strain
Ko et al. Suppression of amber codons in Caulobacter crescentus by the orthogonal Escherichia coli histidyl-tRNA synthetase/tRNAHis pair
Weihmann et al. The modular pYT vector series employed for chromosomal gene integration and expression to produce carbazoles and glycolipids in P. putida
Zavilgelsky et al. Sequencing and comparative analysis of the lux operon of Photorhabdus luminescens strain Zm1: ERIC elements as putative recombination hot spots
WO2022138649A1 (en) A plasmid for transformation, a method for producing a transformant using the same, and a method of transformation
Jeong et al. Quorum sensing inhibition through site-directed mutation by deletion PCR
AU2018200668B2 (en) Composition for solubilizing target protein and use thereof
WO2016093606A1 (en) Method for preparing recombinant proteins through reduction of rnpa gene expression
JP4980483B2 (en) Yeast and its breeding method

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: MEDICOSBIOTECH, INC., KOREA, REPUBLIC OF

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY;REEL/FRAME:047890/0974

Effective date: 20181220

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION